Loading
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.
Previous close
$2.23
−$0.12 · -5.11%
Regular session · ET · Market data may be delayed.
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.
Day range
Current $2.23
52-week range
Current $2.23
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Sell
Trim exposure — unfavorable risk-reward
Valuation
21
Expensive
Sentiment
67
Bullish
Risk
63
High Risk
Momentum
26
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.
Day range
Current $2.23
52-week range
Current $2.23
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 408.21K USD | 674K USD | 743K USD | 810K USD | 853K USD |
| Cost of goods sold | 24.19K USD | — | — | — | — |
| Gross profit | 384.02K USD | 674K USD | 743K USD | 810K USD | 853K USD |
| Research and development | 6.75M USD | 5.76M USD | 5.98M USD | 7.76M USD | 9.85M USD |
| Selling, general, and administrative | 3.67M USD | 3.05M USD | 2.96M USD | 3.14M USD | 3.85M USD |
| Operating expenses | 10.41M USD | 8.8M USD | 8.94M USD | 10.91M USD | 13.7M USD |
| Interest income | 286.25K USD | 291K USD | 506K USD | 222K USD | 24K USD |
| Interest expense | 14.11K USD | 14K USD | 14K USD | 77K USD | 18K USD |
| Depreciation and amortization | 24.19K USD | 7K USD | 15K USD | 14K USD | 14K USD |
| Operating income | −10.03M USD | −8.13M USD | −8.2M USD | −10.1M USD | −12.84M USD |
| Net income | −9.91M USD | −7.88M USD | −7.63M USD | −10.17M USD | −12.6M USD |
Company facts updated Sep 6, 2026.
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 4 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 5, 2026 | 1:20 | — | — |
Stock split | Jan 9, 2023 | 1:10 | — | — |
Stock split | May 10, 2019 | 1:15 | — | — |
Effective Jan 5, 2026
1:20
Effective Jan 9, 2023
1:10
Effective May 10, 2019
1:15
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR Portfolio Emerging Markets ETFSPEM1.96M0.01%17.77B USD0.07%$53.41+0.77%
State Street SPDR S&P Emerging Markets Small Cap ETFEWX475.47K0.07%680.67M USD0.65%$74.065+0.75%
State Street SPDR S&P Emerging Asia Pacific ETFGMF383.87K0.09%431.45M USD0.49%$159.17+0.97%
State Street SPDR Portfolio MSCI Global Stock Market ETFSPGM105.64K0.01%1.76B USD0.09%$88.20+0.01%State Street SPDR Portfolio Emerging Markets ETFSPEMState Street SPDR S&P Emerging Markets Small Cap ETFEWXState Street SPDR S&P Emerging Asia Pacific ETFGMFState Street SPDR Portfolio MSCI Global Stock Market ETFSPGMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
